Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.53 |
| ▸ | TUBB | P07437 | 3/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL9707943 | 0.98 | PTGS2 (0.64) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL15271424 | 0.85 | PTGS2 (0.50) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL3127096 | 0.84 | HTR2A (0.64) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL4464142 | 0.82 | HTR2A (0.75) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL8910416 | 0.82 | PTGS2 (0.70) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL9085046 | 0.82 | PTGS2 (0.47) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL21980854 | 0.82 | PTGS2 (0.47) | PTGS2HTR2AHTR2CHTR2BTUBB4A | |
| SCHEMBL6780613 | 0.81 | HTR2A (0.60) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL8067442 | 0.80 | TUBB4A (0.54) | PTGS2HTR2ATUBB4ATUBBTUBA3C | |
| Bromide SCHEMBL28463593 | 0.80 | PTGS2 (0.46) | PTGS2HTR2AHTR2CHTR2BTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112794837-B | Synthesis method of heterochroman compound | 云南大学 | 2023-05-23 | — | — | CN | claimed |
| CN-112851619-B | Synthesis method of selenium-containing heterochroman compound | 云南大学 | 2023-05-09 | — | — | CN | claimed |
| CN-107311846-B | Gem difluoroethyl substituted stilbene and diphenylethane derivatives, and preparation method and application thereof | 上海华理生物医药股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-112851619-A | Synthetic method of selenium-containing isochroman compound | 云南大学 | 2021-05-28 | — | — | CN | claimed |
| CN-112851624-A | Synthetic method of 2-benzoxazepine compound | 云南大学 | 2021-05-28 | — | — | CN | claimed |
| CN-112794837-A | Synthesis method of isochroman compound | 云南大学 | 2021-05-14 | — | — | CN | claimed |
| CN-112538025-A | Preparation method of fluorine-containing compound for hydrophobic surface treatment agent | 湖北福力德鞋业有限责任公司 | 2021-03-23 | — | — | CN | claimed |
| US-6743937-B2 | WATER SOLUBILITY; ANGIOGENESIS INHIBITOR, ANTICANCER AGENTS | OXIGENE, INC. | 2004-06-01 | — | — | US | claimed |
| US-20020119951-A1 | Efficient method of synthesizing combretastatin A-4 prodrugs | MATEON THERAPEUTICS, INC. | 2002-08-29 | — | — | US | claimed |
| WO-2002006279-A1 | EFFICIENT METHOD OF SYNTHESIZING COMBRETASTATIN A-4 PRODRUGS | OXIGENE INC (US) | 2002-01-24 | — | — | WO | claimed |
| WO-1992016486-A1 | SUBSTITUTED DIPHENYLETHYLENES AND ANALOGUES OR DERIVATIVES THEREOF | ASTON MOLECULES LIMITED (GB) | 1992-10-01 | — | — | WO | claimed |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4153565-B1 | BENZYLPYRIDINIUM REAGENT FOR MASS SPECTROMETRY | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12424426-B2 | Benzylpyridinium reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| EP-0253084-A2 | 1,3-Disubstituted imidazolium salts | F. HOFFMANN-LA ROCHE AG (CH) | 1988-01-20 | — | — | EP | disclosed |
| US-4335052-A | OXIDATION OF CORRESPONDING BENZYL HALIDE WITH TERITARY AMINE OXIDEIN PRESENCE OF WATER | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1982-06-15 | — | — | US | disclosed |
| US-4059593-A | Synthesis of steganacin and derivatives thereof | UNIVERSITY OF ROCHESTER (US) | 1977-11-22 | — | — | US | disclosed |
| US-4003916-A | ANTI-LEUKEMIC AGENTS; DIBENZO-CYCLOOCTADIENE LIGNIN LACTONES; SAPONIFICATION | KENDE ANDREW S | 1977-01-18 | — | — | US | disclosed |
| US-3957790-A | VASODILATORS | TOKYO TANABE COMPANY, LTD. (JA) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119951-A1 | Efficient method of synthesizing combretastatin A-4 prodrugs | CA4, CA6, SLC5A6 | PTGS2 2473/4885HTR2A 2948/4885HTR2C 4093/4885 |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | CHRM5, CHRM3, CHRNA3 | PTGS2 4509/4885HTR2A 66/4885HTR2C 32/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | PTGS2 1385/4885HTR2A 4734/4885HTR2C 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.